| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP19A1 |
| Uniprot No | P11511 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-503aa |
| 氨基酸序列 | MVLEMLNPIHYNITSIVPEAMPAATMPVLLLTGLFLLVWNYEGTSSIPGPGYCMGIGPLISHGRFLWMGIGSACNYYNRVYGEFMRVWISGEETLIISKSSSMFHIMKHNHYSSRFGSKLGLQCIGMHEKGIIFNNNPELWKTTRPFFMKALSGPGLVRMVTVCAESLKTHLDRLEEVTNESGYVDVLTLLRRVMLDTSNTLFLRIPLDESAIVVKIQGYFDAWQALLIKPDIFFKISWLYKKYEKSVKDLKDAIEVLIAEKRRRISTEEKLEECMDFATELILAEKRGDLTRENVNQCILEMLIAAPDTMSVSLFFMLFLIAKHPNVEEAIIKEIQTVIGERDIKIDDIQKLKVMENFIYESMRYQPVVDLVMRKALEDDVIDGYPVKKGTNIILNIGRMHRLEFFPKPNEFTLENFAKNVPYRYFQPFGFGPRGCAGKYIAMVMMKAILVTLLRRFHVKTLQGQCVESIQKIHDLSLHPDETKNMLEMIFTPRNSDRCLEH |
| 预测分子量 | 62.0 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CYP19A1重组蛋白的3篇参考文献示例(注：文献信息为模拟生成，仅供参考)：
---
1. **文献名称**: *Heterologous Expression and Purification of Human CYP19A1 in Escherichia coli for Functional Studies*
**作者**: Zhang L, Wang Y, et al.
**摘要**: 本研究成功在大肠杆菌系统中表达了人源CYP19A1重组蛋白，通过优化诱导条件和亲和层析技术实现高纯度蛋白制备。研究验证了重组蛋白的催化活性，并分析了其与雄烯二酮底物的结合动力学参数。
---
2. **文献名称**: *Structural Insights into CYP19A1 through Baculovirus-mediated Expression in Insect Cells*
**作者**: Thompson R, Korzekwa K, et al.
**摘要**: 利用杆状病毒-昆虫细胞系统高效表达CYP19A1重组蛋白，结合X射线晶体学解析了其与芳香酶抑制剂的复合物结构，揭示了底物结合口袋的关键氨基酸残基，为靶向药物设计提供依据。
---
3. **文献名称**: *Functional Characterization of CYP19A1 Mutants Using Recombinant Protein Assays*
**作者**: Santen RJ, Brodie H, et al.
**摘要**: 通过哺乳动物细胞表达系统(HEK293)生成多种CYP19A1突变体重组蛋白，评估其酶活变化与临床疾病(如芳香化酶过量综合征)的关联，发现特定突变导致雌激素合成异常升高的分子机制。
---
**说明**：以上文献为示例，实际引用时需核实真实来源及发表信息。建议通过PubMed或Web of Science检索关键词“CYP19A1 recombinant protein”获取最新研究。
CYP19A1. also known as aromatase, is a cytochrome P450 enzyme critical for estrogen biosynthesis. It catalyzes the conversion of androgens (androstenedione and testosterone) into estrogens (estrone and estradiol), a process essential for sexual development, reproductive function, and maintaining hormonal balance. This membrane-bound protein is primarily expressed in gonads, placenta, adipose tissue, and brain, with tissue-specific regulation influencing local estrogen production. Dysregulation of CYP19A1 is linked to hormone-dependent disorders such as breast cancer, endometriosis, and osteoporosis, making it a key therapeutic target.
Recombinant CYP19A1 proteins are engineered to study the enzyme’s structure-function relationships, substrate specificity, and inhibition mechanisms. Produced via heterologous expression systems (e.g., E. coli, yeast, or mammalian cells), these proteins retain catalytic activity when reconstituted with essential cofactors like NADPH-cytochrome P450 reductase and a lipid environment mimicking endoplasmic reticulum membranes. Structural studies using X-ray crystallography and cryo-EM have revealed its unique features, including a hydrophobic substrate-binding pocket, a proton relay network for catalysis, and a flexible loop region governing substrate access.
Pharmaceutical research leverages recombinant CYP19A1 to develop aromatase inhibitors (e.g., letrozole, anastrozole) for treating estrogen receptor-positive breast cancer. Challenges in producing functional recombinant CYP19A1 include proper folding, membrane association, and stability, often addressed through mutagenesis or fusion tags. Its role in extragonadal estrogen synthesis also underscores its relevance in neuroendocrine and metabolic studies. Overall, recombinant CYP19A1 serves as a vital tool for advancing endocrinology, oncology, and drug discovery.
×
